Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Euclidean Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Euclidean Capital

Euclidean Capital

Operating

Euclidean Capital LLC: A family investment firm founded by mathematician, James Simons.

Location
New York City, NY, US
Founded
2009
Firm
Compare
Portfolio
Employees

Investments

Nura Bio
Nura Bio
Series B

Total Raised

$146.8M

Rounds

2

Series B$73.8MJune 2026
Series A$73MJuly 2020
Sion Power
Sion Power

Total Raised

$145M

Rounds

3

Series A$75MJanuary 2024
Actio Biosciences
Actio Biosciences

Total Raised

$55M

Rounds

1

Series A$55MSeptember 2023
Spiral
Spiral

Total Raised

$42M

Rounds

3

Series A$28MMarch 2023
Codagenix
Codagenix

Total Raised

$65.6M

Rounds

12

Series B$25MFebruary 2023
Zeitview
Zeitview
Series E

Total Raised

$114M

Rounds

9

Series E$55MFebruary 2023
Series Unknown$20MOctober 2021
Setpoint Medical
Setpoint Medical

Total Raised

$344M

Rounds

12

Series Unknown$80MJanuary 2023
Series Unknown$64MJanuary 2021
Casma Therapeutics
Casma Therapeutics

Total Raised

$154.9M

Rounds

4

Series C$46MNovember 2022
Redesign Health
Redesign Health

Total Raised

$315M

Rounds

2

Series C$65MSeptember 2022
ArsenalBio
ArsenalBio

Total Raised

$305.8M

Rounds

2

Series B$220.8MSeptember 2022
April
April

Total Raised

$40M

Rounds

2

Series A$30MJune 2022
Seed$10MJanuary 2022
Possible Finance
Possible Finance

Total Raised

$157.5M

Rounds

13

Series Unknown$20MMay 2022
Kallyope
Kallyope

Total Raised

$487.2M

Rounds

6

Series D$236MFebruary 2022
Duality Technologies
Duality Technologies

Total Raised

$50M

Rounds

3

Series B$30MOctober 2021
Ripple Foods
Ripple Foods

Total Raised

$313M

Rounds

11

Series E$60MSeptember 2021
Circle Pharma
Circle Pharma

Total Raised

$117.5M

Rounds

6

Series C$66MJune 2021
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Series C$65MJune 2021
Stablix
Stablix

Total Raised

$63M

Rounds

1

Series A$63MJune 2021
Asapp
Asapp

Total Raised

$380M

Rounds

4

Series C$120MMay 2021
A2 Biotherapeutics
A2 Biotherapeutics

Total Raised

$190.5M

Rounds

4

Series B$71.5MOctober 2020
Surrozen
Surrozen
Public

Total Raised

$253M

Rounds

5

Series C$50MJune 2020